DNA mismatch repair deficiency in endometrial carcinoma

International Journal of Gynecological Pathology

Volumn 28, Issue 3, 2009, Pages 239-255

  Karamurzin, Yevgeniy ^a   Rutgers, Joanne K L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Atypical endometrial hyperplasia; Endometrial carcinoma; Endometrial hyperplasia; Hereditary nonpolyposis colorectal carcinoma; HNPCC; K ras; Lynch syndrome; Microsatellite instability; Mismatch repair; MLH1; MMR; MSH2; MSH6; MSI; Ovarian carcinoma; PMS1; PMS2; PTEN

Indexed keywords

K RAS PROTEIN; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS1; MISMATCH REPAIR PROTEIN PMS2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN CTNNB1; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; SOMATOMEDIN B RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CHROMOSOMAL LOCALIZATION; CLINICAL FEATURE; COLORECTAL CANCER; DNA METHYLATION; ENDOMETRIUM CARCINOMA; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION;

DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICROSATELLITE INSTABILITY;

EID: 69049099970     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31818d8fe6     Document Type: Article

References (161)

1. Peltomaki P, Aaltonen LA, Sistonen P, et al. Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993;260:810-812 (Pubitemid 23167610)
2. Aaltonen LA, Peltomäki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816 (Pubitemid 23167611)
3. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561 (Pubitemid 23186645)
4. Thibodeau SN, Bren G, Schaid DJ. Microsatellite instability in cancer of the proximal colon. Science 1993;260: 816-819 (Pubitemid 23167612)
5. Risinger JI, Berchuck A, Kohler MF, et al. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-5103 (Pubitemid 23333372)
6. Kunkel TA. DNA replication fidelity. J Bio Chem 1992;26:18251-18254
7. Schofield MJ, Hsieh P. DNA mismatch repair: molecular mechanisms and biologic function. Annu Rev Microbiol 2003;57:579-608. (Pubitemid 37406637)
8. Pfeifer JD. Molecular Genetic Testing in Surgical Pathology. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:35-46.
9. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005;74:681-710.
10. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6. (Pubitemid 28062870)
11. Raevaara TE, Korhonen MK, Lohi H, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005;129:537-549 (Pubitemid 41096642)
12. Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer 2006;119:2030-2035 (Pubitemid 44423658)
13. Tajima A, Hess MT, Cabrera BL, et al. The mismatch repair complex hMutSa recognizes f-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004;127:1678-1684 (Pubitemid 39575846)
14. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O6-methylguanine. Mol Cell 2004;14:105-116
15. Li GM. The role of mismatch repair in DNA damage-induced apoptosis. Oncol Res 1999;11:393-400.
16. Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ 2001;8:1076-1092 (Pubitemid 33061825)
17. Velasco A, Pallares J, Santacana M, et al. Loss of heterozygosity in endometrial carcinoma. Int J Gynecol Pathol 2008;27:305-317
18. Koul A, Willen R, Bendahl PO, et al. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369-2379 (Pubitemid 34457118)
19. Hirasawa A, Aoki D, Inoue J, et al. Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res 2003;9:5675-5682 (Pubitemid 37499490)
20. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma. Cancer 2000;88:814-824
21. Lax SF, Kurman RJ. A dualistic model for endometrial cancerogenesis based on immunohistochemical and molecular genetic analyses. Verch Dtsch Ges Pathol 1997;81:228-232
22. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-390 (Pubitemid 30818176)
23. Mutter GL. PTEN, a protein tumor suppressor. Am J Pathol 2001;158:1895-1898
24. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930
25. Orbo A, Eklo K, Kopp M. A semiautomated test for microsatellite instability and its significance for the prognosis of sporadic endometrial cancer in Northern Norway. Int J Gynecol Pathol 2002;21:27-33. (Pubitemid 34008350)
26. MacDonald ND, Salvesen HB, Ryan A, et al. Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population series. Int J Gynecol Cancer 2004;14:957-965
27. Wagner HFA, Barrows A, Wijnen J, et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003;72:1088-1100 (Pubitemid 36529998)
28. Huang J, Kuismanen SA, Liu T, et al. MSH6 and MSH3 are rarely involved in genetic predisposition to nonpolypotic colon cancer. Cancer Res 2001;61:1619-1623 (Pubitemid 34292596)
29. Miyaki M, Konishi M, Tanaka K, et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997;17:271-272
30. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999;23:142-144 (Pubitemid 29455383)
31. Berends MJ, Wu Y, Sijmons RH, et al. Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet 2002;70:26-37. (Pubitemid 34031695)
32. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003;100:5908-5913
33. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7817 (Pubitemid 44289242)
34. Jass JR. What's new in hereditary colorectal cancer? Arch Pathol Lab Med 2005;129:1380-1384
35. Peltomäki P, Gao X, Mecklin JP. Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam Cancer 2001;1:9-15.
36. Esteller M, Frage MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10:3001-3007 (Pubitemid 34083486)
37. Rahner N, Friedrichs N, Steinke V, et al. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome. J Pathol 2008;214:10-16
38. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 1999;155:1767-1772
39. Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998;17:2413-2417 (Pubitemid 28515395)
40. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of the expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811 (Pubitemid 27097998)
41. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993;3:226-231 (Pubitemid 23108662)
42. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997;88:471-481 (Pubitemid 27154412)
43. Helmle KE, Otto CJ, Constaninescu G, et al. Variable MLH1 promoter methylation patterns in endometrial carcinomas of endometrioid subtype lacking DNA mismatch repair. Int J Gynecol Cancer 2005;15:1089-1096
44. Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene 2003;22:2352-2360 (Pubitemid 36566790)
45. Buttin BM, Powell MA, Goodfellow PJ, et al. Increased risk for abnormalities on perioperative colon screening in patients with microsatellite instability-positive endometrial carcinoma. Int J Gynecol Cancer 2006;16:1980-1986
46. Buttin BM, Powell MA, Mutch DG, et al. Increased risk for hereditary colorectal cancer - associated synchronous and metachronous malignancies in patients with microsatellite instability - positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 2004;10:481-490
47. Whelan AJ, Babb S, Mutch DG, et al. MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers. Int J Cancer 2002;99:697-704. (Pubitemid 34538749)
48. Walsh MD, Cummings MC, Buchanan DD, et al. Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res 2008;14:1692-1700
49. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet 1999;36:801-818 (Pubitemid 29520569)
50. Watson P, Lynch HT. Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 2001;1:57-60.
51. Lu HK, Broaddus RR. Gynecologic cancers in Lynch syndrome/HNPCC. Fam Cancer 2005;4:249-254
52. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81:214-218 (Pubitemid 29144749)
53. Dunlop MG, Farrington SM, Carothers AD, et al. Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 1997;6:105-110 (Pubitemid 27033972)
54. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456 (Pubitemid 29258894)
55. Bonis PA, Trikalinos TA, Chung M, et al. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep) 2007;150:1-180.
56. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268 (Pubitemid 38256271)
57. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute of microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257
58. Dietmaier W, Hofstädter F. Detection of microsatellite instability by real time PCR and hybridization probe melting point analysis. Lab Invest 2001;81:1453-1456 (Pubitemid 32980167)
59. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027 (Pubitemid 26113739)
60. Kuismanen SA, Moisio AL, Schweizer P, et al. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 2002;160:1953-1958 (Pubitemid 34663387)
61. Berends MJ, Hollema H, Wu Y, et al. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer 2001;92:398-403. (Pubitemid 32249717)
62. Berends MJ, Wu Y, Sijmons RH, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 2003;21:4364-4370 (Pubitemid 46621813)
63. Modica I, Soslow RA, Black D, et al. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007;31:744-751 (Pubitemid 46684215)
64. Stefansson I, Akslen LA, MacDonald N, et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res 2002;8:138-143 (Pubitemid 34101469)
65. de Leeuw WJ, Dierssen J, Vasen HF, et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumors from HNPCC patients. J Pathol 2000;192:328-335
66. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A 1992;89:1827-1831
67. Clark SJ, Harrison J, Paul CL, et al. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-2997 (Pubitemid 24260626)
68. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-9826 (Pubitemid 26296693)
69. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acid Res 1997;25:2532-2534 (Pubitemid 27303718)
70. Shi X, Li J, Zhao C, et al. Methylation analysis of hMLH1 gene promoter by a bisulfite-sensitive single-strand conformation polymorphism-capillary electrophoresis method. Biomed Chromatogr 2006;20:815-820 (Pubitemid 44203179)
71. Worm J, Aggerholm A, Guldberg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin Chem 2001;47:1183-1189 (Pubitemid 32579104)
72. Uhlmann K, Marczinek K, Hampe J, et al. Changes in methylation patterns identified by two-dimensional DNA fingerprinting. Electrophoresis 1999;20:1748-1755 (Pubitemid 29320469)
73. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007;13:3221-3228 (Pubitemid 46944905)
74. Perucho M. Tumors with microsatellite instability: many mutations, targets, and paradoxes. Oncogene 2003;22:2223-2225 (Pubitemid 36566778)
75. Catasus L, Matias-Guiu X, Machin P, et al. Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. Cancer 2000;88:2290-2297 (Pubitemid 30247129)
76. Black D, Bogomolniy F, Robson ME, et al. Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecol Oncol 2005;96:21-24 (Pubitemid 39612412)
77. Kanaya T, Kyo S, Sakaguchi J, et al. Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population. Am J Clin Pathol 2005;124:89-96. (Pubitemid 40944379)
78. Risinger JI, Hayes AK, Berchuk A, et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-4738
79. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-3940 (Pubitemid 27427679)
80. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143-144
81. Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between MSI and PTEN gene mutations in endometrial carcinomas. Int J Cancer 2006;119:563-570 (Pubitemid 43955709)
82. Peiro G, Lohse P, Mayr D, et al. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Am J Clin Pathol 2003;120:78-85.
83. Cohn DE, Basil JB, Venegoni AR, et al. Absence of PTEN repeat tract mutation in endometrial cancers with microsatellite instability. Gynecol Oncol 2000;79:101-106
84. Zhou XP, Kuismanen S, Nystrom-Lahti M, et al. Distinct PTEN mutational spectra in HNPCC syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet 2002;11:445-450 (Pubitemid 34213618)
85. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutation and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 1998;58:3254-3258
86. Gurin CC, Federici MG, Kang L, et al. Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 1999;59:462-466 (Pubitemid 29048884)
87. Schwartz SJ, Yamamoto H, Navarro M, et al. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999;59:2995-3002. (Pubitemid 29283143)
88. Myeroff LL, Parsons R, Kim SJ, et al. A transforming growth factor b receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res 1995;55:5545-5547
89. Catasus L, Matias-Guiu X, Machin P, et al. BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest 1998;78:1439-1444 (Pubitemid 28546087)
90. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
91. Caduff RF, Johnson CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671-1678 (Pubitemid 26135906)
92. Mutter GL, Wada H, Facquin WC, et al. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mod Pathol 1999;52:257-262 (Pubitemid 29469917)
93. Swisher EM, Peiffer-Schneider S, Mutch D, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 1999;85:119-126 (Pubitemid 29031365)
94. Sakamoto T, Murase T, Urushibata H, et al. Microsatellite instability and somatic mutations in endometrial carcinomas. Gynecol Oncol 1998;71:53-58 (Pubitemid 28492393)
95. Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 2001;193:193-199 (Pubitemid 32118131)
96. Duggan BD, Felix JC, Muderspach LI, et al. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-1221 (Pubitemid 24253696)
97. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577 (Pubitemid 32601237)
98. Mirabelli-Primadhl L, Gryfe R, Kim H, et al. β-Catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-3351 (Pubitemid 29334489)
99. Kobayashi K, Sagae S, Nishioka Y, et al. Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 1999;90:55-59 (Pubitemid 29084311)
100. Machin P, Catasus L, Pons C, et al. CTNNB1 mutations and b-catenin expression in endometrial carcinomas. Hum Pathol 2002;33:206-212 (Pubitemid 34298736)
101. Wu Y, Berends MJ, Mensink RG, et al. Association of hereditary non-polyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 mutations. Am J Hum Genet 1999;65:1291-1298 (Pubitemid 30460379)
102. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068-5074 (Pubitemid 29503960)
103. Parc YR, Halling KC, Wang L, et al. HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res 2000;60:2225-2231 (Pubitemid 30225187)
104. Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997;57:3920-3923 (Pubitemid 27427676)
105. Lucci-Cordisco E, Rovella V, Carrara S, et al. Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Fam Cancer 2001;1:93-99
106. Charames GS, Millar AL, Pal T, et al. Do MSH6 mutations contribute to double primary cancers of the colorectum and endometrium? Hum Genet 2000;107:623-629
107. Peiro G, Diebold J, Lohse P, et al. Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 2002;33:347-354 (Pubitemid 34461470)
108. Baldinu P, Cossu A, Manca A, et al. Microsatellite instability and mutation analysis of candidate genes in unselected Sardinian patients with endometrial carcinoma. Cancer 2002;94:3157-3168 (Pubitemid 34670499)
109. Tashiro H, Lax SF, Gaudin PB, et al. Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 1997;150:75-79 (Pubitemid 27027098)
110. Catasus L, Machin P, Matias-Guiu X, et al. Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases. Hum Pathol 1998;29:1160-1164 (Pubitemid 28467540)
111. Kobayashi K, Sagae S, Kudo R, et al. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosomes Cancer 1995;14:128-132
112. Wong YF, Ip TY, Chung TK, et al. Clinical and pathologic significance of microsatellite instability in endometrial cancer. Int J Gynecol Cancer 1999;9:406-410
113. Basil JB, Goodfellow PG, Rader JS, et al. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000;89:1758-1764 (Pubitemid 30794170)
114. MacDonald ND, Salvesen MG, Ryan A, et al. Frequency and prognosis impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res 2000;60:1750-1752 (Pubitemid 30183451)
115. Fiumicino S, Ercoli A, Ferrandina G, et al. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. J Clin Oncol 2001;19:1008-1014 (Pubitemid 32176275)
116. Maxwell GL, Risinger JI, Alvarez AA, et al. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol 2001;97:417-422 (Pubitemid 32184704)
117. Muresu R, Sini MC, Cossu A, et al. Chromosomal abnormalities and microsatellite instability in sporadic endometrial cancer. Eur J Cancer 2002;38:1802-1809 (Pubitemid 34886523)
118. Pijnenborg JM, Daam-de Veen GC, de Haan J, et al. Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol 2004;94:550-559 (Pubitemid 39024566)
119. Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24:1745-1753 (Pubitemid 46622146)
120. Tibiletti MG, Furlan D, Taborelli M, et al. Microsatellite instability in endometrial cancer: relation to histological subtypes. Gynecol Oncol 1999;73:247-252 (Pubitemid 29215739)
121. Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer 2007;1220:1684-1688 (Pubitemid 46399354)
122. Zighelboim I, Goodfellow PJ, Gao F, et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007;25:2042-2048 (Pubitemid 46972789)
123. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106:87-94. (Pubitemid 43032552)
124. Vasen HF, Watson P, Mecklin JP, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994;14:1675-1678 (Pubitemid 24357004)
125. Broaddus RR, Lu KH. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. Front Biosci 2006;11:2077-2080
126. McCourt CK, Mutch DG, Gibb RK, et al. Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol 2007;104:535-539
127. Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006;108:1208-1215
128. Cohn DE, Pavelka JC, Frankel WL, et al. Correlation between patient weight and defects in DNA mismatch repair: is this the link between an increased risk of previous cancer in thinner women with endometrial cancer? Int J Gynecol Cancer 2008;18:136-140
129. Lu K, Schorge JO, Rodabaugh KJ, et al. Prospective determination of prevalence of Lynch syndrome in young women with endometrial cancer. J Clin Oncol 2007;25:5158-5164 (Pubitemid 350232246)
130. Honore LH, Hanson J, Andrew SE. Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer 2006;16:1386-1392 (Pubitemid 43886774)
131. An HJ, Kim KI, Kim Jy, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol 2007;31:846-853
132. Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 2008;39:116-125 (Pubitemid 350216167)
133. Kihana T, Fujioka T, Hamada K, et al. Association of replication error positive phenotype with lymphocyte infiltration in endometrial cancers. Jpn J Cancer Res 1998;89:895-902. (Pubitemid 28486814)
134. Westin S, Broaddus R. Adenocarcinoma of the lower uterine segment. A unique subset of endometrial carcinoma [abstract]. Mod Pathol 2008;215:227A.
135. Jass JR. HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences. Fam Cancer 2004;3:93-100.
136. Parc YR, Halling KC, Burgart LJ, et al. Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. Int J Cancer 2000;86:60-66
137. van den Bos M, van den Hoven M, Jongejan E, et al. More differences between HNPCC-related and sporadic carcinomas from the endometrium as compared to the colon. Am J Surg Pathol 2004;28:706-711. (Pubitemid 38685884)
138. Valentini AM, Armentano R, Pirrelli M, et al. Chemotherapeutic agents for colorectal cancer with a defective mismatch repair system: the state of the art. Cancer Treat Rev 2006;32:607-618 (Pubitemid 44649135)
139. Pors K, Patterson LH. DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents. Curr Top Med Chem 2005;5:1133-1149 (Pubitemid 41644888)
140. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886 (Pubitemid 26374423)
141. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996;56:3087-3090 (Pubitemid 26199755)
142. Moreland NJ, Illand M, Kim YT, et al. Modulation of drug resistance mediated by loss of mismatch by the DNA polymerase inhibitor aphidicolin. Cancer Res 1999;59:2102-2106 (Pubitemid 29217672)
143. Yang JL, Friedlander ML. Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene. Lancet 2001;357:1767-1768 (Pubitemid 32524212)
144. Sergent C, Franco N, Chapusot C, et al. Human colon cancer cells surviving high doses of cisplatin or oxaplatin in vitro are not defective in DNA mismatch repair proteins. Cancer Chemother Pharmocol 2002;49:445-452 (Pubitemid 34671279)
145. Jacob S, Aguado M, Fallik D, et al. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 2001;61:6555-6562 (Pubitemid 32783264)
146. Plumb JA, Steele N, Finn PW, et al. Epigenetic approaches to cancer therapy. Biochem Soc Trans 2004;32:1095-1097
147. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999;21:103-107 (Pubitemid 29036293)
148. Robinson W, Im MM, Ljungman M, et al. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res 2003;63:6935-6941 (Pubitemid 37322979)
149. Berry SE, Davis TW, Shupp JE, et al. Selective radiosensitization of drug-resistant MutS homologue 2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Cancer Res 2000;60:5773-5780
150. Mesquita B, Veiga I, Pereira D, et al. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin. BMC Cancer 2005;5:101. (Pubitemid 41461034)
151. Li HR, Shagisultanova EI, Yamashita K, et al. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res 2004;64:4760-4767 (Pubitemid 38924519)
152. Sutter C, Dallenbach-Hellweg G, Schmidt D, et al. Molecular analysis of endometrial hyperplasia in HNPCC-suspicious patients may predict progression to endometrial carcinoma. Int J Gynecol Pathol 2004;23:18-25. (Pubitemid 38018232)
153. Orbo A, Nilsen MN, Arnes MS, et al. Loss of expression of MLH1, MSH2, MSH6, and PTEN related to endometrial cancer in 68 patients with endometrial
154. Horowitz N, Pinto K, Mutch DG, et al. Microsatellite instability, MLH1 promoter methylation, and loss of mismatch repair in endometrial cancer and concomitant atypical hyperplasia. Gynecol Oncol 2002;86:62-68
155. Banno K, Yanokura M, Susumu N, et al. Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep 2006;16:1189-1196
156. Irving JA, Catasus L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the β-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005;36:605-619 (Pubitemid 40922566)
157. Kaneki E, Oda Y, Ohishi Y, et al. Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis. Hum Pathol 2004;35:1484-1493 (Pubitemid 40017988)
158. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol 2008;32:1029-1037
159. Furlan D, Carnevali I, Marcomini B, et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006;12:3329-3336 (Pubitemid 43910876)
160. Soliman PT, Broaddus RR, Schmeler KM, et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol 2005;23:9344-9350
161. Martini M, Ciccarone M, Garganese G, et al. Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer 2002;102:398-406.